NCT03476681 - Study of NEO-201 in Solid Tumors Expansion Cohorts | Biotech Hunter

Enrollment

121

Participants

Timeline

Start Date

January 18, 2019

Primary Completion Date

January 15, 2028

Study Completion Date

January 15, 2029

Conditions

Non Small Cell Lung CancerHead and Neck Squamous Cell CarcinomaCervical CancerUterine Cancer

Interventions

DRUG

NEO-201 in combination with pembrolizumab

NEO-201 will be given intravenously every 2 weeks in combination with pembrolizumab. In each cycle subjects will receive 3 doses of NEO 201 and one dose of pembrolizumab.

Trial Locations (2)

20892

RECRUITING

National Cancer Institute, Bethesda

22031

RECRUITING

INOVA Schar Cancer Institute, Fairfax